Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
Edesa Biotech, Inc. (NASDAQ:EDSA) announced the appointment of Rajan Puri as Senior Vice President of Manufacturing to enhance its manufacturing operations. Puri, an expert in Chemistry, Manufacturing, and Controls (CMC), brings over 20 years of experience from previous roles at CMAB Biopharma and Therapure Biopharma. His expertise is expected to be crucial for advancing Edesa's clinical and commercialization plans, particularly in inflammatory and immune-related diseases. The company is focusing on drugs like EB05 for Acute Respiratory Distress Syndrome and EB01 for chronic allergic contact dermatitis.
- Appointment of Rajan Puri as Senior VP of Manufacturing expected to enhance operational capabilities.
- Puri's extensive background in biopharmaceutical manufacturing and business development adds strategic value.
- Focus on scaling up manufacturing aligns with anticipated growth opportunities for Edesa's product pipeline.
- Potential risks in achieving regulatory approvals for product candidates remain.
- Dependence on Puri's leadership raises concerns regarding continuity and experience gaps in management.
TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.
Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry, Manufacturing and Controls (CMC) in the biopharmaceutical field and will lead the company's strategic planning and operations related to scale-up, manufacturing and quality control.
"We are pleased to welcome Raj to our management team in anticipation of multiple potential growth opportunities this year. He brings a wealth of strategic and operational expertise with process development, scale-up and GMP production that will be critical to the advancement of our clinical and commercialization plans," said Michael Brooks, President of Edesa Biotech.
Mr. Puri is a biopharma executive with more than 20 years of experience leading cross-functional initiatives and teams in biologics manufacturing, business development, regulatory affairs and product marketing. Prior to joining Edesa, Mr. Puri served as Vice President of Business Development for CMAB Biopharma, a start-up contract development and manufacturing organization (CDMO) sold to Wuxi Biologics. He was an original member of the Therapure Biopharma executive team, another biologic CDMO, and helped successfully grow the business from 20 employees to over 250 during a ten year tenure. Prior to his experience with CDMO's, Mr. Puri worked in both biotech and large pharma companies including regulatory affairs at Eli Lilly. In addition to his career positions, Mr. Puri was a board member for the Pharma & Biopharma Outsourcing Association (PBOA), a non-profit trade association representing pharmaceutical contract manufacturing organizations. He holds an MBA in Science and Technology, and a Master of Science degree in Pharmacology and Toxicology from Queen's University, Kingston, Canada.
Mr. Puri said that Edesa provides an exciting opportunity to work in a pivotal area of inflammatory and autoimmune diseases. "I'm excited to join Edesa at such a transformational time for the company. I look forward to working with the Edesa team and contributing to the advancement of Edesa's pipeline and helping expand the company's ability to deliver important new drug products for patients worldwide," he said.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: the company's timing and plans regarding its clinical studies, and the company's plans to increase manufacturing activities and capabilities. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
SOURCE: Edesa Biotech
View source version on accesswire.com:
https://www.accesswire.com/652709/Edesa-Biotech-Team-Expands-Leadership-Team-with-Key-Manufacturing-Appointment
FAQ
Who is Rajan Puri and what is his role at Edesa Biotech?
What experience does Rajan Puri bring to Edesa Biotech?
How will Rajan Puri's appointment impact Edesa Biotech's operations?
What are Edesa Biotech's lead product candidates?
What challenges does Edesa Biotech face with its product candidates?
